Clinical trials: Central Obesity
Insulin Resistance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.
- Trial name
- NCT01271777
- Testing
- GFT505 80mg
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Genfit
Obesity
Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study
The objectives of this clinical research project are to demonstrate the safety and feasibility of CAVU Medical, Inc.'s Attune Device.
- Trial name
- NCT01422941
- Testing
- CAVU Attune Device
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Cavu Medical, Inc.
Obesity, Morbid Obesity
Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102
The main objective of this study is to evaluate the LGL102 implant safety in obese to morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight changes will be also evaluated.
- Trial name
- NCT01539850
- Testing
- OMS102
- Where
- 3 sites in Germany
- Volunteers
- 34 people
- Sponsor
- IntraPace, Inc
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Prader-Willi Syndrome
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management.
- Trial name
- NCT05322096
- Testing
- RGH-706
- Where
- 23 sites in United States, Czechia and 3 more
- Volunteers
- 39 people
- Sponsor
- Gedeon Richter Plc.
Overweight/Obesity
Bioequivalence Study of BGM0504 Injection
This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference…
- Trial name
- NCT07382908
- Testing
- BGM0504 Injection multi-dose pen, BGM0504 Injection single-dose pen
- Where
- China
- Volunteers
- 144 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Hypothalamic Injury-induced Obesity (HIO)
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
Double-blind, randomized, placebo-controlled, single- center study followed by an open-label extension period. The study will have two parts: Part 1: 24 weeks double-blind treatment (DB), followed by Part 2: 24 weeks open-label…
- Trial name
- NCT03845075
- Testing
- Tesofensine/Metoprolol
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Saniona
Adverse Drug Event, Side Effects of Drugs
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.
- Trial name
- NCT03112083
- Testing
- Nutritional counseling A, Nutritional counselling B
- Where
- Finland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Olympic Seafood AS
Prader-Willi Syndrome
Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.
- Trial name
- PWS (NCT05198362)
- Testing
- Tesomet
- Where
- United States
- Sponsor
- Saniona
Hypothalamic Obesity
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO
- Trial name
- NCT05147415
- Testing
- Tesomet
- Where
- United States
- Sponsor
- Saniona
Obesity
Effect of Tesofensine on Energy Balance in Humans.
Purpose: To evaluate the effect of tesofensine on energy balance
- Trial name
- NCT00428415
- Testing
- Tesofensine
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NeuroSearch A/S
Atrial Fibrillation, Obesity
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who…
- Conditions
- Atrial Fibrillation, Obesity, Anticoagulants
- Trial name
- NCT04681482
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 107,383 people
- Sponsor
- Pfizer
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight or Obesity
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo.
- Trial name
- VESPER-3 (NCT06973720)
- Testing
- MET097
- Where
- 5 sites in United States
- Volunteers
- 268 people
- Sponsor
- Pfizer
Health Adult Subjects, Obesity & Overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Trial name
- NCT07675590
- Testing
- TIX100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- TIXiMED, Inc.
Obesity, Overweight
A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease
The purpose of this observational study is to measure how many people are overweight or obese amongst patients with a diagnosed cardiovascular disease (CVD).
- Trial name
- POETIC (NCT05873660)
- Testing
- No treatment given
- Where
- 5 sites in United States, Brazil and 3 more
- Volunteers
- 5,360 people
- Sponsor
- Novo Nordisk A/S
Thrombosis
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
SAD study: Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II or III.
- Trial name
- NCT03903302
- Testing
- CS1-Sodium Valproate
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cereno Scientific AB
Obesity, Diabetes Mellitus Type 2
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug
The primary objective of this study is to assess the efficacy of Rimonabant (SR141716) compared to placebo on change in HbA1c and on relative change in body weight over 52 weeks in obese type 2 diabetic patients on monotherapy…
- Trial name
- SYMPHONY (NCT00478595)
- Testing
- Rimonabant, Anti-diabetic monotherapy
- Where
- Japan
- Volunteers
- 458 people
- Sponsor
- Sanofi
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes, Metabolism and Nutrition Disorder
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects…
- Conditions
- Diabetes, Metabolism and Nutrition Disorder, Obesity
- Trial name
- NCT02079870
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S